Hotspot pocket-based discovery of urea transporter selective inhibitors

  • Nat Commun. 2026 Apr 20;17(1):5444. doi: 10.1038/s41467-026-71834-w.
Lei Liu  #  1  2  3 Zhi Li  #  4 Chao Zhang  #  5 Yan Zhang  #  6 Zhizhen Huang  #  7 Daolai Zhang  6 Dongfang Li  1 Juanjuan Zhao  6 Yuhao Miao  6 Boyang Cai  8 Kongkai Zhu  2 Jin-Peng Sun  2  8 Guige Hou  9 Ying Sun  10 Baoxue Yang  11 Xiao Yu  12 Shenming Huang  13  14
Affiliations
  • 1. State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, Jinan University, Guangzhou, China.
  • 2. Advanced Medical Research Institute, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
  • 3. The Second Qilu Hospital of Shandong University, Jinan, China.
  • 4. Jiangsu Key Laboratory of Geriatric Precision Medicine and Aging Intervention, Xuzhou Medical University, Xuzhou, Jiangsu, P. R. China.
  • 5. Institute of Brain Science and Brain-inspired Research, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, PR China.
  • 6. School of Pharmacy, The Key Laboratory of Prescription Effect and Clinical Evaluation of State Administration of Traditional Chinese Medicine of China, Shandong Medical and Pharmaceutical University, Yantai, China.
  • 7. Department of Pharmacology, School of Basic Medical Sciences, State Key Laboratory of Natural and Biomimetic Drugs, and State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China.
  • 8. Department of Physiology and Pathophysiology, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University, Beijing, China.
  • 9. School of Pharmacy, The Key Laboratory of Prescription Effect and Clinical Evaluation of State Administration of Traditional Chinese Medicine of China, Shandong Medical and Pharmaceutical University, Yantai, China. [email protected].
  • 10. Jiangsu Key Laboratory of Geriatric Precision Medicine and Aging Intervention, Xuzhou Medical University, Xuzhou, Jiangsu, P. R. China. [email protected].
  • 11. Medical Innovation Center (Taizhou) of Peking University, Taizhou, China. [email protected].
  • 12. Key Laboratory Experimental Teratology of the Ministry of Education and Department of Physiology, School of Basic Medical Sciences, Shandong University, Jinan, China. [email protected].
  • 13. State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, Jinan University, Guangzhou, China. [email protected].
  • 14. Advanced Medical Research Institute, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. [email protected].
  • # Contributed equally.
Abstract

Urea Transporter (UT) inhibitors are a promising class of diuretics, as selective inhibitors targeting UT-A subtypes have demonstrated considerable therapeutic potential. Herein, we employ a two-round progressive hotspot pocket-based virtual screening approach combined with biological validation to identify M353-0039 as a highly potent and selective inhibitor of UT-A2. We conduct cryo-electron microscopy to solve the structures of UT-A2 bound with the two inhibitors, M353-0039 and E822-1968, at the resolution of 2.7 Å and 2.9 Å respectively, and elucidate the structural mechanism underlying the superior efficacy and selectivity of M353-0039. Compared with the inhibitor HQA2 and E822-1968, M353-0039 occupies a deeper binding pocket and forms more interactions with UT-A2, thus leading to greater inhibitory potency. We demonstrate that the selectivity of M353-0039 is driven by the nonconserved residues C285 and G322 within the "T-T" subpocket of UT-A2. Finally, we validate the selective effects of M353-0039 in inhibiting UT-A2 function both in mouse models and hepatic cell. These findings not only identify a selective inhibitor as a tool that can be applied to elucidate the unique physiological roles of UT-A2 but also provide an available method for efficiently developing UT-A-selective inhibitors with potent activity as the next-generation diuretics.

Products